Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegunigalsidase Alfa in Fabry Disease
NCT03566017Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Sep 2018
- Primary completion
- Jan 2025
- Modality
- PEGylated Peptides, Replacement Enzymes
- Countries
- 13
01
Overview
A Phase 3 trial of pegunigalsidase alfa in Fabry disease (FD), sponsored by Chiesi Farmaceutici S.p.A.. Started Sep 2018; status: completed.
02
Drugs
pegunigalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT03566017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03566017.